Aspen Pharmacare Holdings Ltd $ 9.60 0 (0%)
Volume:
2,454
Avg Vol (1m):
6,942
Market Cap $:
4.37 Bil
Enterprise Value $:
6.66 Bil
P/E (TTM):
14.14
P/B:
0.95
Financial Strength | 5/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 0.17 | ||
Equity-to-Asset | 0.52 | ||
Debt-to-Equity | 0.61 | ||
Debt-to-EBITDA | 5.89 | ||
Interest Coverage | 5.68 | ||
Piotroski F-Score | 6 | ||
Altman Z-Score | 1.74 | ||
Beneish M-Score | -2.51 | ||
WACC vs ROIC |
Profitability Rank | 7/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | 23.19 | ||
Net Margin % | 12.07 | ||
ROE % | 7.8 | ||
ROA % | 3.75 | ||
ROC (Joel Greenblatt) % | 22.67 | ||
3-Year Revenue Growth Rate | -2.1 | ||
3-Year EBITDA Growth Rate | -3.2 | ||
3-Year EPS without NRI Growth Rate | -3.5 |
APNHY
Valuation Rank | 10/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
PE Ratio | 14.14 | ||
PE Ratio without NRI | 14.3 | ||
Price-to-Owner-Earnings | 22.14 | ||
PB Ratio | 0.95 | ||
PS Ratio | 1.71 | ||
Price-to-Free-Cash-Flow | 11.84 | ||
Price-to-Operating-Cash-Flow | 7.99 | ||
EV-to-EBIT | 14.07 | ||
EV-to-EBITDA | 14.07 | ||
EV-to-Revenue | 2.61 | ||
Shiller PE Ratio | 12 | ||
Current Ratio | 2.03 | ||
Quick Ratio | 1.12 | ||
Days Inventory | 285.62 | ||
Days Sales Outstanding | 85.49 | ||
Days Payable | 63.57 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Dividend Growth Rate | -100 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Intrinsic-Value-Projected-FCF | 0.86 | ||
Price-to-Median-PS-Value | 0.45 | ||
Earnings Yield (Greenblatt) % | 7.11 | ||
Forward Rate of Return (Yacktman) % | -1.41 |